Keyphrases
Multiple Sclerosis
100%
Natalizumab
100%
B Cells
100%
Plasmablast
100%
B Cell Subsets
54%
Progressive multiple Sclerosis
36%
Relapsing-remitting MS
36%
Cerebrospinal Fluid
36%
Natalizumab Treatment
36%
CD49d
36%
Memory B Cells
27%
Absolute Count
18%
Blood Fluid
18%
MS Patients
18%
Healthy Controls
9%
Flow Cytometry
9%
Multiple Sclerosis Treatment
9%
High-level Expression
9%
Relapsing-remitting multiple Sclerosis
9%
Cell Count
9%
Relapse Pattern
9%
Longitudinal Cohort
9%
IgG Concentration
9%
Unstable Patients
9%
Frequency Count
9%
Memory Cell
9%
All-subsets
9%
Absolute Cell Count
9%
Immunology and Microbiology
B Cell
100%
Natalizumab
100%
Multiple Sclerosis
100%
Plasmablast
100%
B Lymphocyte Subpopulation
46%
Cerebrospinal Fluid
30%
Memory B Cell
30%
CD49d
30%
Blood Plasma
15%
Cell Count
15%
Relapsing Remitting Multiple Sclerosis
7%
Neuroscience
Multiple Sclerosis
100%
Natalizumab
100%
B Cell
100%
B Lymphocyte Subpopulation
46%
Relapsing Remitting Multiple Sclerosis
7%
Flow Cytometry
7%